#Sweden #Gothenburg #Oblique Therapeutics #Dr. Jan Lundberg #TRPV1

Oblique Therapeutics Strengthens Its Scientific Team

Oblique Therapeutics has taken a significant leap forward in its mission to develop innovative solutions for pain and inflammatory disorders with the announcement of Dr. Jan Lundberg joining the company as Scientific Advisor. This strategic recruitment highlights the company’s emphasis on advancing its groundbreaking drug platform.

Dr. Lundberg brings a wealth of experience, having established a remarkable international career that spans both academia and the global pharmaceutical landscape. He started as a researcher and professor at the renowned Karolinska Institute, quickly rising to prominence as one of the world's most cited scientists.

Following his tenure at the Karolinska Institute, Dr. Lundberg transitioned to the pharmaceutical sector, where he held key research and development roles at AstraZeneca and later at Eli Lilly in the United States. At Eli Lilly, he played a pivotal role as the Global Head of Research, significantly contributing to the organization’s remarkable ascent to becoming the world's most highly valued pharmaceutical company.

Under his leadership, Eli Lilly successfully launched several GLP-1 receptor agonists, including therapies similar to Ozempic, which have gained widespread recognition in treating metabolic diseases like obesity. Dr. Lundberg’s portfolio also includes developing treatments for Alzheimer’s disease, chronic pain, and pioneering antibody therapies for migraines and severe cluster headaches. His vast knowledge in drug development and strategic portfolio management is expected to greatly benefit Oblique Therapeutics as they continue their path forward.

Oblique’s commitment to addressing pain management through cutting-edge therapies continues to gain momentum. With a keen focus on developing next-generation antibody-based ion channel therapeutics, particularly targeting TRPV1, the company aims to revolutionize treatments for those living with chronic pain. Dr. Lundberg's extensive network and experience in translational research align perfectly with Oblique's vision and operations.

In his own words, Dr. Lundberg expressed his excitement about joining Oblique Therapeutics, stating, "I have been active in the research field surrounding capsaicin, TRPV1, and pain since its very early days, and it is extremely exciting to see the progress now being made by Oblique Therapeutics. The company’s antibody-based strategy has the potential to create a new and clear differentiation compared to small molecule TRPV1 blockers."

His statement reflects the innovative approach Oblique Therapeutics is taking in modifying pain treatment paradigms, shifting away from traditional methods that have been limited by various side effects.

Oblique Therapeutics CEO, Christer Nordstedt, expressed pride in Dr. Lundberg’s decision to collaborate with the company. "We are extremely pleased and proud that Dr. Jan Lundberg has chosen to engage with Oblique Therapeutics. His unique scientific stature and proven experience in building successful pharmaceutical portfolios are invaluable to our ongoing development."

Dr. Lundberg hails from Munkfors, in Sweden's Värmland province, a region noted for producing many successful individuals, including historical figures in politics and arts. Interestingly, before pursuing a medical career, he was an accomplished ice hockey player, showcasing his multifaceted skills both on and off the ice.

With Dr. Lundberg's expertise in pain management and drug development, Oblique Therapeutics is poised to make significant advancements in delivering effective therapies for patients dealing with chronic pain and inflammatory diseases. The future seems promising as the company strives to pave new pathways in pharmaceuticals, focusing on patient-centric solutions that promise better quality of life for many.

For more information about Oblique Therapeutics and Dr. Jan Lundberg’s contributions, visit Oblique’s official website.